Nintedanib Esylate

CAS 656247-17-5 17 API suppliersSmall Molecule

Overview

Nintedanib Esylate is a tyrosine kinase inhibitor used in the treatment of idiopathic pulmonary fibrosis and certain types of non-small cell lung cancer. It inhibits multiple receptor pathways, leading to reduced tumor angiogenesis and fibrosis.

API suppliers (17)

Suppliers of Nintedanib Esylate evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India7China4Finland1USA1United Kingdom1Taiwan1Netherlands1

Country recorded for 16 of 17 suppliers.

9 of 17 hold a GMP certificate on record in the EU or UK registers

Therapeutic areas

PulmonologyOncology
Verified Supplier Partner

Do you supply Nintedanib Esylate? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.